59037-70-6

Basic information

• Product Name: 1-FURAN-2-YLMETHYL-PIPERAZINE
• Synonyms: TIMTEC-BB SBB007008;ART-CHEM-BB B004010;1-(2-FURYLMETHYL)PIPERAZINE;1-FURFURYLPIPERAZINE;1-FURAN-2-YLMETHYL-PIPERAZINE;AKOS B004010;1-(2-furylmethyl)piperazine(SALTDATA: 2HCl);Piperazine, 1-(2-furanylmethyl)-
• CAS NO: 59037-70-6
• Molecular Formula: C₉H₁₄N₂O
• Molecular Weight: 166.22
• Mol File: 59037-70-6.mol
• Article Data: 6

Chemical Properties

• Boiling Point: 243.5°C at 760 mmHg
• Flash Point: 101.1°C
• Appearance: /
• Vapor Pressure: 0.032mmHg at 25°C
• CAS DataBase Reference: 1-FURAN-2-YLMETHYL-PIPERAZINE(CAS DataBase Reference)
• NIST Chemistry Reference: 1-FURAN-2-YLMETHYL-PIPERAZINE(59037-70-6)
• EPA Substance Registry System: 1-FURAN-2-YLMETHYL-PIPERAZINE(59037-70-6)

Safety Data

• Hazard Codes: Xi,Xn
• Statements: 22
• HazardClass: IRRITANT
• Hazardous Substances Data: 59037-70-6(Hazardous Substances Data)

Usage

General Description

1-Furan-2-ylmethyl-piperazine is a chemical compound consisting of a piperazine ring with a furan-2-ylmethyl group attached to it. It is commonly used as a building block in the synthesis of pharmaceuticals and agrochemicals due to its potential biological activity. 1-FURAN-2-YLMETHYL-PIPERAZINE has been found to exhibit anticonvulsant and antidepressant properties in some studies. Additionally, it has shown potential as an antidote for organophosphate poisoning. 1-Furan-2-ylmethyl-piperazine is also used in the manufacture of dyes, pigments, and other fine chemicals. However, it is important to handle this compound with care as it may be hazardous if not properly handled or stored.

InChI:InChI=1/C9H14N2O/c1-2-9(12-7-1)8-11-5-3-10-4-6-11/h1-2,7,10H,3-6,8H2/p+2

Upstream product

• 110-85-0 piperazine 
• 98-01-1 furfural 
• 163839-20-1 tert-butyl 4-(furan-2-ylmethyl)piperazine-1-carboxylate 
• 98-00-0 (2-furyl)methyl alcohol 

Relevant articles and documents

Discovery of Novel Apigenin-Piperazine Hybrids as Potent and Selective Poly (ADP-Ribose) Polymerase-1 (PARP-1) Inhibitors for the Treatment of Cancer

Poly (ADP-ribose) polymerase-1 (PARP-1) is a potential target for the discovery of chemosensitizers and anticancer drugs. Amentoflavone (AMF) is reported to be a selective PARP-1 inhibitor. Here, structural modifications and trimming of AMF have led to a series of AMF derivatives (9a-h) and apigenin-piperazine/piperidine hybrids (14a-p, 15a-p, 17a-h, and 19a-f), respectively. Among these compounds, 15l exhibited a potent PARP-1 inhibitory effect (IC50 = 14.7 nM) and possessed high selectivity to PARP-1 over PARP-2 (61.2-fold). Molecular dynamics simulation and the cellular thermal shift assay revealed that 15l directly bound to the PARP-1 structure. In in vitro and in vivo studies, 15l showed a potent chemotherapy sensitizing effect against A549 cells and a selective cytotoxic effect toward SK-OV-3 cells through PARP-1 inhibition. 15l·2HCl also displayed good ADME characteristics, pharmacokinetic parameters, and a desirable safety margin. These findings demonstrated that 15l·2HCl may serve as a lead compound for chemosensitizers and the (BRCA-1)-deficient cancer therapy.

TRIAZOLE DERIVATIVES HAVING ANTIFUNGAL ACTIVITY, METHOD FOR THE PREPARATION THEREOF, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME

A triazole derivative of formula 1 or a pharmaceutically acceptable salt, hydrate, solvate or isomer thereof is superior to the conventional antifungal drugs in antifungal activity against a wide spectrum of pathogenic fungi, and has advantageously low toxicity.

2-,3-,4-,5-,6-,7-,8-,9- and/or 10-substituted dibenzoxazepine and dibenzthiazepine compounds, pharmaceutical compositions and methods of use

The present invention provides substituted dibenzoxazepine and dibenzthiazepine compounds of Formula I: STR1 which are useful as analgesic agents for the treatment of pain, and for prostaglandin-E2 mediated diseases, pharmaceutical compositions comprising a therapeutically-effective amount of a compound of Formula I in combination with a pharmaceutically-acceptable carrier, a method for eliminating or ameliorating pain in an animal comprising administering a therapeutically-effective amount of a compound of Formula I to the animal, and a method for treating prostaglandin-E2 mediated diseases in an animal comprising administering a therapeutically-effective amount of a compound of Formula I to the animal.